Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial

Authors not listed

University of Colorado, Denver · 2024

Abstract

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2024). Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial. <em>University of Colorado, Denver</em>. https://clinicaltrials.gov/study/NCT05822362
Vancouver
Anonymous. Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial. University of Colorado, Denver. 2024.
BibTeX
@misc{anon2024Cannab, title = {Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial}, author = {Anonymous}, journal = {University of Colorado, Denver}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings